Healios K.K.
JPX: 4593.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tadahisa S. Kagimoto
- Employees
- 65
- Headquarters
- Tokyo, Japan
- IPO year
- 2015
- Market cap
- ¥37B
- Website
- https://www.healios.co.jp
Loading 4593…
Loading profile data…Frequently asked questions about 4593
What does Healios K.K. (4593.T) do?
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular dege...
Where does 4593.T trade?
Healios K.K. (4593.T) trades on the Tokyo Stock Exchange.
What sector is 4593.T in?
Healios K.K. (4593.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Healios K.K.?
Tadahisa S. Kagimoto is the chief executive officer of Healios K.K. (4593.T).
Where is Healios K.K. headquartered?
Healios K.K. is headquartered in Japan.
Does 4593.T pay a dividend?
Healios K.K. (4593.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4593.T go public?
Healios K.K. (4593.T) completed its initial public offering in 2015.